Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences
BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma (Nasdaq: ALBO), a clinical-stage company focused on novel bile acid modulators, announced CEO Ron Cooper's participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma (Nasdaq: ALBO), a clinical-stage company focused on novel bile acid modulators, announced CEO Ron Cooper's participation in the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021. Additionally, he will present at the LifeSci Advisors 10th Annual Corporate Access Event on January 8, 2021, at 12:00 pm EST. Both events will be available for replay on Albireo's website for two weeks after. The company is developing treatments for rare liver diseases, with key products in pivotal trials.
Details
News Market Reaction – ALBO
The recorded move for ALBO in the trading session of this news was -0.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in the H.C. Wainwright Virtual BioConnect 2021 Conference to be held January 11-14, 2021 and the LifeSci Advisors 10th Annual Corporate Access Event to be held January 6-14, 2021.
The virtual LifeSci Advisors event presentation will be live at 12:00 pm EST on January 8, 2021 from the Albireo Media and Investors page ir.albireopharma.com and the H.C. Wainwright fireside chat will be available beginning Monday, January 11, 2021 also at ir.albireopharma.com. Both sessions will be archived and available for replay on Albireo’s website for two weeks following the events.
About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.
Media & Investor contacts:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Hans Vitzthum, LifeSci Advisors, LLC., 857-272-6177
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.